Lemborexant Shows Promise for Patients with Insomnia Short Sleep Who Do Not Respond to CBT–Insomnia - Psychiatry Advisor

The current study aimed to assess rates of response and remission with Lemborexant based on the Insomnia Severity Index in the insomnia short sleep subgroup.

Lemborexant (LEM) may benefit patients with insomnia short sleep (ISS) who do not respond to cognitive behavioral therapyinsomnia (CBT-I), according to research recently presented at the 2022 Annual … [+2251 chars]

full article...